A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT01309412 · TERMINATED

Trial details

NCT number: NCT01309412
Sponsor: Janssen Pharmaceutical K.K.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2011-01-01
Primary completion: 2012-12-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.